Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Seikagaku to Run Add’l PIII for Lumbar Disc Herniation Drug in US
February 20, 2018
- Fujifilm Starts Japan PII for Radiopharmaceutical in Pheochromocytoma
February 20, 2018
- Dovobet Gel Wins Japan Approval: LEO/Kyowa Kirin
February 20, 2018
- Medical System Network Taps into Generic Business via Its Dispensing Pharmacy Chains, Aiming at Future Expansion
February 20, 2018
- Takeda’s Specialty Biz Unit Most Likely to Handle GI Meds, Entyvio Launch Apparently Eyed
February 20, 2018
- Takeda to Revamp Sales Offices as Japan Shifts to Community-Based Care System
February 20, 2018
- Lenvima OK’ed for UK Health Coverage in Thyroid Cancer
February 19, 2018
- Oncolys Invests in US Immuno-Oncology Startup
February 19, 2018
- Sumitomo Dainippon Halts Development of FXR Agonist in Japan, South Korea
February 16, 2018
- Daiichi Sankyo Files Mirogabalin in Japan for PNP
February 16, 2018
- Global Brands Drive Otsuka’s Pharma Sales in 2017
February 15, 2018
- Astellas Picks Up US Upstart, Grabs Full Access to Universal Donor Cell Technology
February 15, 2018
- Sumitomo Dainippon Sues 2 Gx Makers over Latuda, Delays New 5-Year-Plan Announcement
February 15, 2018
- Teijin, SanBio Terminate License Agreement for Stroke Treatment; Development and Marketing Rights to Revert to SanBio
February 15, 2018
- Lonasen Patch Hits PIII Primary Target in Japan, Filing Planned in 1st Half of FY2018: Sumitomo Dainippon, Nitto Denko
February 15, 2018
- New Dosage Strength Approved for Enbrel Pen: Pfizer
February 14, 2018
- Adcetris Filed in Japan for Frontline Hodgkin’s Lymphoma: Takeda
February 14, 2018
- Zytiga Shows Consistent Efficacy in Japanese High-Risk mHNPC Patients
February 14, 2018
- New IITs for Oncolytic Virus to Begin for Head and Neck Cancer, Sarcoma: Oncolys
February 13, 2018
- Pricing Revamp for Off-Patent Brands “Within Our Expectation”: LTL Pharma CEO
February 13, 2018
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…